VJHemOnc is committed to improving our service to you

ISA 2020 | ANDROMEDA study: updated safety run-in results

VJHemOnc is committed to improving our service to you

Vaishali Sanchorawala

The Phase III ANDROMEDA (NCT03201965) study investigated subcutaneous daratumumab in combination with cyclophosphamide, bortezomib and dexamethasone (CyBorD) for patients with newly-diagnosed light-chain (AL) amyloidosis. In this video, Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, discusses the updated safety run-in results of the ANDROMEDA study. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter